Standard Operating Procedure for Tracking Changes to Submission Standards and Formats
| Department | Regulatory Affairs |
| SOP No. | RA/2026/637 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 09/04/2026 |
| Effective Date | 09/04/2026 |
| Review Date | 09/04/2028 |
Purpose
This Standard Operating Procedure (SOP) describes the process to systematically identify, assess, document, and track changes to regulatory submission standards and formats. The objective is to ensure that all modifications in regulatory requirements, document templates, or submission formats are captured timely, evaluated for impact, and incorporated into submission practices to maintain compliance and facilitate efficient regulatory interactions.
Scope
This SOP applies to all regulatory affairs personnel involved in the preparation, review, and submission of regulatory dossiers and documents across all products, dosage forms, and geographic regions. It covers changes originating from regulatory agencies, pharmacopeial updates, internal procedural adjustments to submission formats, and applicable electronic submission standards. Activities outside regulatory submission standards and formats, such as clinical protocol changes or product formulation management, are not included.
Responsibilities
- Regulatory Affairs Officers: Monitor regulatory databases, agency notifications, and relevant updates to identify changes in submission standards and formats.
- Regulatory Analysts: Assess and document the impact of identified changes on current submissions and regulatory strategies.
- Regulatory Affairs Manager: Review and approve assessment outcomes and coordinate implementation of required changes.
- Quality Assurance (QA): Verify adherence to this SOP and compliance of updated submission documents and processes.
- Document Control: Manage version control and archival of relevant submission templates and SOP updates.
Accountability
The Regulatory Affairs Head holds overall accountability for the implementation, monitoring, compliance, and periodic review of this SOP. They are responsible for escalation of unresolved issues, ensuring training on updates, and confirming effectiveness of controls related to submission standards and formats.
Procedure
1. Preparation and Prerequisites:
Regulatory Affairs personnel shall subscribe to applicable regulatory agency newsletters, official gazettes, electronic portals, and professional networks to stay informed about any changes to submission standards and formats. Ensure access to current submission templates, SOPs, and document control systems.
2. Identification of Changes:
Upon receipt or discovery of a change notification, Regulatory Affairs Officers shall document the source, nature, and date of the change in a tracking log designed for submission standards and formats.
3. Impact Assessment:
Regulatory Analysts review the change details to determine its relevance and potential impact on ongoing or planned submissions. This includes evaluating the need to revise submission templates, electronic file formats, data organization, or regulatory strategies. The assessment shall consider timelines, affected products, and geographic regions.
4. Documentation and Communication:
The outcome of the impact assessment shall be documented in a formal assessment report and communicated to the Regulatory Affairs Manager and other stakeholders as applicable. If changes require procedural or template updates, initiate revision control processes.
5. Approval and Implementation:
The Regulatory Affairs Manager reviews and approves the assessment and any proposed adjustments. On approval, revised submission templates and SOP amendments shall be implemented. Relevant personnel shall be trained on the updated requirements and processes promptly.
6. Verification and Compliance Checks:
QA shall periodically audit adherence to the updated SOP and ensure submission documents comply with the latest standards and formats. Any deviations are to be documented and corrected.
7. Record Keeping and Closure:
All records, including change notifications, assessment reports, approval communications, revised templates, training records, and audit findings, shall be maintained per regulatory and company document retention policies. The change event is closed formally once post-implementation verification confirms compliance.
8. Continuous Monitoring:
Maintain an ongoing monitoring process to capture subsequent updates or corrections to submission standards and formats, ensuring the SOP and submission documentation remain current and compliant.
Abbreviations
- SOP – Standard Operating Procedure
- QA – Quality Assurance
- RA – Regulatory Affairs
- eCTD – Electronic Common Technical Document
- GMP – Good Manufacturing Practice
Documents
The following documents are required to implement and control the process of tracking changes to submission standards and formats:
- Change Notification Log for Submission Standards and Formats (Annexure-1)
- Impact Assessment Report Template (Annexure-2)
- Revised Submission Template Version Control Register (Annexure-3)
References
- International Council for Harmonisation (ICH) guidelines on electronic submissions (e.g., ICH M4)
- 21 CFR Part 11 – Electronic Records; Electronic Signatures
- EMA and FDA official submission guidance documents
- Company Quality Management System Documentation Control Procedures
- Pharmaceutical Regulatory Requirements and Guidelines applicable to submission formats
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Change Notification Log for Submission Standards and Formats
| Field | Description / Dummy Data |
| Date Received | 05/04/2026 |
| Source of Change | FDA Electronic Submission Guidance Update |
| Change Reference Number | FDA-ES-2026-001 |
| Summary of Change | Revised eCTD module structure and file naming conventions |
| Affected Submission Types | New drug applications (NDA), Abbreviated new drug applications (ANDA) |
| Initial Reviewer | Regulatory Affairs Officer |
| Comments | Update impacts submission software configurations |
Annexure-2: Impact Assessment Report Template
| Field | Description / Dummy Data |
| Date of Assessment | 07/04/2026 |
| Assessment Conducted By | Regulatory Analyst |
| Nature of Change | Modification of electronic submission dossier format including updated validation rules |
| Impact Summary | Requires revision of submission templates and training of RA team |
| Affected Products / Regions | All pharmaceutical products submitted to FDA and EMA from 01/05/2026 |
| Recommended Actions | Revise templates, update SOPs, conduct training session by 15/04/2026 |
| Findings & Comments | No impact on submission timelines anticipated |
| Reviewed & Approved By | Regulatory Affairs Manager |
Annexure-3: Revised Submission Template Version Control Register
| Field | Description / Dummy Data |
| Template Name | eCTD Module 1 – Cover Letter |
| Version Number | 2.1 |
| Effective Date | 09/04/2026 |
| Revision Summary | Updated section numbering and file format requirements |
| Prepared By | Regulatory Document Control |
| Approved By | Regulatory Affairs Manager |
| Next Review Date | 09/04/2028 |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 09/04/2026 | 1.0 | Initial issue | New SOP creation |